Why the study?
Does the self-reported Morisky score accurately identify nonadherence with chronic cardiovascular medications compared to prescription refill data in patients on ACE inhibitors or lipid-lowering agents?
Does the self-reported Morisky score accurately identify nonadherence with chronic cardiovascular medications compared to prescription refill data in patients on ACE inhibitors or lipid-lowering agents?
The 4-item Morisky scale has limited utility as a standalone screening tool for cardiovascular medication nonadherence due to poor sensitivity, positive predictive value, and internal consistency.
No takes yet. Share an insight, caveat, or question.
Clinicians should avoid sole reliance on Morisky scores for CV adherence screening; leaves open need for validated alternatives.
Shalansky et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: